Testosterone supplementation for hypoactive sexual desire disorder in women

Pharmacotherapy

Volumn 32, Issue 1, 2012, Pages 38-53

  Woodis, C Brock ^a,b   McLendon, Amber N ^a,c   Muzyk, Andrew J ^a,d  

^a CAMPBELL UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Glenaire Continuing Care Retirement Community   (United States)

^d DUKE UNIVERSITY HOSPITAL   (United States)

Author keywords

Androgen; Female sexual dysfunction; FSD; HSDD; Hypoactive sexual desire disorder; Testosterone

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; PLACEBO; PRASTERONE; PROGESTERONE; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ACNE; ANDROGEN THERAPY; APPLICATION SITE REACTION; BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HIRSUTISM; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; LABORATORY TEST; LOW DRUG DOSE; MEDICAL EXAMINATION; MEDICAL HISTORY; MONOTHERAPY; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL SATISFACTION; SIDE EFFECT; SKIN MANIFESTATION; SKIN TINGLING; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TESTOSTERONE;

EID: 84860720929     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/PHAR.1004     Document Type: Review

References (75)

1. Woodis CB. Hormone therapy for the management of menopausal symptoms: pharmacotherapy update. J Pharm Pract 2010;23:540-7.
2. Krapf JM, Simon JA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas 2009;63:213-19.
3. Novi JM, Book NM. Sexual dysfunction in perimenopause: a review. Obstet Gynecol Surv 2009;64:624-31.
4. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women. Obstet Gynecol 2008;112:970-8.
5. Jha S, Thakar R. Female sexual dysfunction. Eur J Obstet Gynecol Reprod Biol 2010;153:117-23.
6. Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynecol Obstet 2010;110:7-11.
7. Davis SR, Nijland E. Pharmacological therapy for female sexual dysfunction: has progress been made? Drugs 2008;68:259-64. (Pubitemid 351225808)
8. Masters EH, Johnson VE. Human sexual response. Boston, MA: Little Brown & Co., 1966.
9. Berman JR, Bassuk J. Physiology and pathophysiology of female sexual function and dysfunction. World J Urol 2002;20:111-18.
10. Stahl SM. Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder. J Clin Psychiatry 2010;71:821-2.
11. Halaris A. Neurochemical aspects of the sexual response cycle. CNS Spectrums 2003;8:211-16. (Pubitemid 36765038)
12. Oades RD, Halliday GM. Ventral tegmental (A10) system: neurobiology. I. Anatomy and connectivity. Brain Res 1987;434:117-65. (Pubitemid 17064083)
13. Stahl SM. Stahl's essential psychopharmacology, 3rd ed. New York, NY: Cambridge University Press, 2008.
14. Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506-33.
15. Arnow BA, Millheiser L, Garrett A, et al. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience 2009;158:484-502.
16. Serretti A, Chiesa A. Sexual side effects of pharmacological treatments of psychiatric diseases. Clin Pharmacol Ther 2011;89:142-7.
17. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of filbanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 2011;8:15-27.
18. Clayton AH, Dennerstein L, Pyke R, Sand M. Flibanserin: a potential treatment for hypoactive sexual desire disorder in premenopausal women. Women's Health (Lond Engl) 2010;6:639-53.
19. Sarrel PM. Sexuality and menopause. Obstet Gynecol 1990;75: S26-7.
20. Berman JR. Physiology of female sexual function and dysfunction. Int J Impot Res 2005;17:S44-51. (Pubitemid 43049376)
21. Raina R, Pahlajani G, Khan S, Gupta S, Agarwal A, Zippe CD. Female sexual dysfunction: classification, pathophysiology, and management. Fertil Steril 2007;88:1273-84. (Pubitemid 350030108)
22. Warnock JJ. Female hypoactive sexual desire disorder. CNS Drug 2002;16:745-53.
23. Schwenhagen A, Studd J. Role of testosterone in the treatment of hypoactive sexual desire disorder. Maturitas 2009;63:152-9.
24. Shifren JL. The role of androgens in female sexual dysfunction. Mayo Clin Proc 2004;79(suppl):S19-24. (Pubitemid 38401761)
25. Berman JR, Berman L, Goldstein I. Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. Urology 1999;54:385-91. (Pubitemid 29407007)
26. Coenen CMH, Thomas CMG, Born GF, Hollanders JMG, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996;53:171-6. (Pubitemid 26082289)
27. Palacios S. Hypoactive sexual desire disorder and current pharmacotherapeutic options in women. Women's Health 2011;7:95-107.
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000.
29. Clayton AH, Goldfischer ER, Goldstein I, DeRagatis L, Lewis-D'Agostine D, Pyke R. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med 2009;6:730-8.
30. Brotto LA, Bitzer J, Laan E, Leiblum S, Luria M. Women's sexual desire and arousal disorders. J Sex Med 2010;7:586-614.
31. Leiblum SR, Wiegel M. Psychotherapeutic interventions for treating female sexual dysfunction. World J Urol 2002;20:127-136.
32. Nappi RE, Martini E, Terreno E, et al. Management of hypoactive sexual desire disorder in women: current and emerging therapies. Int J Women's Health 2010;2:167-75.
33. Greenblatt RB, Barfield WE, Garner JF, Calk GL, Harrod JP Jr. Evaluation of an estrogen, androgen and estrogen-androgen combination and a placebo in the treatment of menopause. J Clin Endocrinol Metab 1950;10:1547-58.
34. Birnberg CH, Kurzrock R. Low-dosage androgen-estrogen therapy in the older age group. J Am Geriatr Soc 1955;3:656-66.
35. Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990;70:1124-31.
36. Sarrel PM, Wiita B. Vasodilator effects of estrogen are not diminished by androgen in postmenopausal women. Fertil Steril 1997;68:1125-7. (Pubitemid 28013381)
37. Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Vertbaten R. Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry 2000;57:149-53. (Pubitemid 30075265)
38. Heard-Davison A, Heiman JR, Kuffel S. Genital and subjective measurement of the time course effects of an acute dose of testosterone vs placebo in postmenopausal women. J Sex Med 2007;4:209-17. (Pubitemid 46002385)
39. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen- only therapy: sexual behavior and neuroendocrine responses. J Reprod Med 1998;43:847-56. (Pubitemid 28481075)
40. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002;87:1509-16. (Pubitemid 34615230)
41. Flöter A, Nathorst-Böös J, Carlström K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well being. Climacteric 2002;5:357-65. (Pubitemid 36149723)
42. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-52. (Pubitemid 36687880)
43. Burger H, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas 1984;6:351-8. (Pubitemid 15138672)
44. Burger H, Hailes J, Nelson J, Menelaus M. Effect of combined implants of estradiol and testosterone on libido in postmenopausal women. BMJ (Clin Res Ed) 1987;294:936-7. (Pubitemid 17051529)
45. Sherwin BB, Gefland MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47:339-51. (Pubitemid 15233431)
46. Sherwin BB, Gefland MM. The role of androgen in the management of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-400.
47. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
48. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
49. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-9. (Pubitemid 41124151)
50. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944-52. (Pubitemid 40571010)
51. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33. (Pubitemid 41262278)
52. Davis Sr, van der Mooren MJ, van Lunsen RH, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;13: 387-96.
53. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, DeRoatis L. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007;4:1001-8. (Pubitemid 47079633)
54. Kingsberg S. Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2007;4 (suppl 3):227-34. (Pubitemid 46372031)
55. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005-17.
56. Panay N, Al-Azzavi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121-31.
57. El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 2007;10:335-43. (Pubitemid 47123955)
58. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-31.
59. Chudakov B, Ben Zion IZ, Belmaker RH. Transdermal testosterone gel PRN application for hypoactive sexual desire disorder in premenopausal women: a controlled pilot study of the effects on the Arizona sexual experiences scale for females and sexual function questionnaire. J Sex Med 2007;4:204-8. (Pubitemid 46002384)
60. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well being, mood and sexual function in premenopausal women. Menopause 2003;10:390-8.
61. Davis S, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women. Ann Intern Med 2008;148:569-77. (Pubitemid 351669130)
62. Barrett-Connor E, Young R, Notelovitz M, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women: effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999;44:1012-20. (Pubitemid 30030175)
63. Birnberg CH, Kurzrock R. Low-dosage androgen-estrogen therapy in the older age group. J Am Geriatr Soc 1955;3:656-66.
64. Somboonporn W, Davis S, Self MW, Bell R. Testosterone for peri and post-menopausal women. Cochrane Database Syst Rev 2005;4:CD004509.
65. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993;82:919-24. (Pubitemid 23347987)
66. Gefland MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 1997;19:383-404. (Pubitemid 27292582)
67. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in post-menopausal women. Menopause 2000;7:395-401.
68. Barrett-Connor E, Goodman-Grueen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995;311:1193-6.
69. Savvas M, Studd JW, Norman S, Leather AT, Garnett TJ. Increase in bone mass after one year of percutaneous oestriadiol and testosterone implants in postmenopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 1992;99:757-60.
70. Bitzer J, Kenemans P, Mueck AO, for the FSD Education Group. Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy. Maturitas 2008;59:209-18.
71. Davis SR, Wolfe R, Farrugia H, Ferdinand A, Bell R. The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med 2009;6:1850-6.
72. Dimitrakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004;11:531-5. (Pubitemid 40362151)
73. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483-9. (Pubitemid 44125867)
74. Bachmanm G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002;77:660-5. (Pubitemid 34275339)
75. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91:3697-716.